Matches in Wikidata for { <http://www.wikidata.org/entity/Q95404520> ?p ?o ?g. }
Showing items 1 to 79 of
79
with 100 items per page.
- Q95404520 description "wetenschappelijk artikel" @default.
- Q95404520 description "наукова стаття" @default.
- Q95404520 name "Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis" @default.
- Q95404520 name "Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis" @default.
- Q95404520 type Item @default.
- Q95404520 label "Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis" @default.
- Q95404520 label "Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis" @default.
- Q95404520 prefLabel "Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis" @default.
- Q95404520 prefLabel "Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis" @default.
- Q95404520 P1433 Q95404520-14FE12ED-4E37-413E-AA85-3C2A1D4C66CC @default.
- Q95404520 P1476 Q95404520-C49FAF66-B077-4AD3-AE0B-F8188A901ADF @default.
- Q95404520 P2093 Q95404520-0062E084-92EB-4E73-A764-FB7996145F60 @default.
- Q95404520 P2093 Q95404520-011B1822-F79A-49AF-8207-60E265DD39A9 @default.
- Q95404520 P2093 Q95404520-157ED834-387B-4FDB-A888-0EFC80A0DAED @default.
- Q95404520 P2093 Q95404520-225A4C39-FA46-4B8A-9F6A-80224AD02F36 @default.
- Q95404520 P2093 Q95404520-2F5446FC-7680-49D5-B314-5C79B786333B @default.
- Q95404520 P2093 Q95404520-3210C7D4-27D6-4D30-BD0D-50ECE4ED2488 @default.
- Q95404520 P2093 Q95404520-48F8C5C2-F12D-45A2-8AE4-DC1361802992 @default.
- Q95404520 P2093 Q95404520-528321F3-7AD9-4544-9E23-E846F15FC9A7 @default.
- Q95404520 P2093 Q95404520-57F473BA-7618-41D5-8AB4-71DA5F564E47 @default.
- Q95404520 P2093 Q95404520-76389760-F451-4629-8EC9-CBB322D2ADCC @default.
- Q95404520 P2093 Q95404520-8B9A1E48-2782-45C2-BEF6-8D6CA4005B7B @default.
- Q95404520 P2093 Q95404520-9373FA78-8CD7-40F7-A1C1-A4920906A1AC @default.
- Q95404520 P2093 Q95404520-A30115B2-8F6F-4B4E-A5FD-11BC252BF595 @default.
- Q95404520 P2093 Q95404520-ACF21A44-DC08-4D0E-8ACD-6F2A890E0A4E @default.
- Q95404520 P2093 Q95404520-AF3030F1-04A2-4A83-990C-8193F8014EEA @default.
- Q95404520 P2093 Q95404520-B20472B0-8171-40E9-8A83-E9CDACAAB06E @default.
- Q95404520 P2093 Q95404520-B4678B1F-4920-461C-B4E9-FD294E41B4A9 @default.
- Q95404520 P2093 Q95404520-BF09DFEC-28E8-42C5-91AB-69582BE41883 @default.
- Q95404520 P2093 Q95404520-E5121EC5-20B2-4DDD-844F-EE9905948FA4 @default.
- Q95404520 P2093 Q95404520-E760E345-DAC6-46AA-BA6A-76865D32512A @default.
- Q95404520 P2093 Q95404520-FCBF693F-3698-43D1-A9BF-C322067F9A95 @default.
- Q95404520 P304 Q95404520-D46AF28D-A9EB-4796-B3D0-1D17B811ADE8 @default.
- Q95404520 P31 Q95404520-C54104E2-4519-4711-B048-3D5FA17F6BD3 @default.
- Q95404520 P356 Q95404520-AB6504AF-D6C3-4BED-B18B-EA27FE9CB77A @default.
- Q95404520 P433 Q95404520-B3DE568B-798A-4FC3-83A0-734A002D41F5 @default.
- Q95404520 P478 Q95404520-64D47B3C-45DA-4364-A0E0-756F7B922DEF @default.
- Q95404520 P50 Q95404520-1D7A553A-B168-44A1-AE28-2B78F20F167E @default.
- Q95404520 P50 Q95404520-8F63973D-EB7D-4E45-B67F-219B5BCFF16A @default.
- Q95404520 P50 Q95404520-A562A763-DEF6-4A93-98A6-8BB3309A4CC7 @default.
- Q95404520 P577 Q95404520-1C190372-FD1C-4A9B-AA43-B80E000ED18D @default.
- Q95404520 P698 Q95404520-3D5F94A4-F076-46B3-9140-43DFF7D8AB21 @default.
- Q95404520 P921 Q95404520-74B91DAE-93ED-45CB-82B3-B02389143A26 @default.
- Q95404520 P356 BJH.15802 @default.
- Q95404520 P698 30768675 @default.
- Q95404520 P1433 Q4970200 @default.
- Q95404520 P1476 "Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis" @default.
- Q95404520 P2093 "Adrian Bloor" @default.
- Q95404520 P2093 "Alistair Hart" @default.
- Q95404520 P2093 "Amy A Kirkwood" @default.
- Q95404520 P2093 "Andy Dann" @default.
- Q95404520 P2093 "Angus Broom" @default.
- Q95404520 P2093 "Anna H Schuh" @default.
- Q95404520 P2093 "Arvind Arumainathan" @default.
- Q95404520 P2093 "Francesco Forconi" @default.
- Q95404520 P2093 "George Follows" @default.
- Q95404520 P2093 "Harriet Walter" @default.
- Q95404520 P2093 "Helen Marr" @default.
- Q95404520 P2093 "Matthew Cross" @default.
- Q95404520 P2093 "Nimish Shah" @default.
- Q95404520 P2093 "Paneesha Shankara" @default.
- Q95404520 P2093 "Piers E M Patten" @default.
- Q95404520 P2093 "Renata Walewska" @default.
- Q95404520 P2093 "Richard Chasty" @default.
- Q95404520 P2093 "Rosalynd Johnston" @default.
- Q95404520 P2093 "Sat Gohill" @default.
- Q95404520 P2093 "Tal Munir" @default.
- Q95404520 P2093 "the UK CLL Forum" @default.
- Q95404520 P304 "656-669" @default.
- Q95404520 P31 Q13442814 @default.
- Q95404520 P356 "10.1111/BJH.15802" @default.
- Q95404520 P433 "4" @default.
- Q95404520 P478 "185" @default.
- Q95404520 P50 Q38320982 @default.
- Q95404520 P50 Q57040255 @default.
- Q95404520 P50 Q87844982 @default.
- Q95404520 P577 "2019-02-15T00:00:00Z" @default.
- Q95404520 P698 "30768675" @default.
- Q95404520 P921 Q1088156 @default.